How easily people forget that we will soon have three human trials active and how this type of progress requires funding. Show me another company with three separate multi-billion dollar drug candidates in active clinical trials with a fully diluted share count near 150 million and a market cap lower than 200 million. The longterm stock price will only go up. the short term gnashing of teeth - who cares.